Epigenetic investigation into circulating microRNA 197-3p in sera from patients affected by malignant pleural mesothelioma and workers ex-exposed to asbestos
- PMID: 37081052
- PMCID: PMC10119131
- DOI: 10.1038/s41598-023-33116-z
Epigenetic investigation into circulating microRNA 197-3p in sera from patients affected by malignant pleural mesothelioma and workers ex-exposed to asbestos
Abstract
The epigenetic role of microRNAs is established at both physiological and pathological levels. Dysregulated miRNAs and their targets appear to be a promising approach for innovative anticancer therapies. In our previous study, circulating miR-197-3p tested dysregulated in workers ex-exposed to asbestos (WEA). Herein, an epigenetic investigation on this circulating miRNA was carried out in sera from malignant pleural mesothelioma (MPM) patients. MiR-197-3p was quantified in MPM (n = 75) sera and comparatively analyzed to WEA (n = 75) and healthy subject (n = 75) sera, using ddPCR and RT-qPCR techniques. Clinicopathological characteristics, occupational, non-occupational information and overall survival (OS) were evaluated in correlation studies. MiR-197-3p levels, analyzed by ddPCR, were significantly higher in MPM than in WEA cohort, with a mean copies/µl of 981.7 and 525.01, respectively. Consistently, RT-qPCR showed higher miR-197-3p levels in sera from MPM with a mean copies/µl of 603.7, compared to WEA with 336.1 copies/µl. OS data were significantly associated with histologic subtype and pleurectomy. Circulating miR-197-3p is proposed as a new potential biomarker for an early diagnosis of the MPM onset. Indeed, miR-197-3p epigenetic investigations along with chest X-ray, computed tomography scan and spirometry could provide relevant information useful to reach an early and effective diagnosis for MPM.
© 2023. The Author(s).
Conflict of interest statement
The following authors: G.D.M., F.F., E.T., E.M., R.L., F.M., I.B., and M.T. declare that data from this study has been employed, in part, for the Italian patent application number RBI17430-IT. M.R.I., A.C., C.M., F.G., V.E. declare no conflict of interest.
Figures




Similar articles
-
Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.Oncotarget. 2016 Dec 13;7(50):82700-82711. doi: 10.18632/oncotarget.12408. Oncotarget. 2016. PMID: 27716620 Free PMC article.
-
Circulating microRNA-197-3p as a potential biomarker for asbestos exposure.Sci Rep. 2021 Dec 14;11(1):23955. doi: 10.1038/s41598-021-03189-9. Sci Rep. 2021. PMID: 34907223 Free PMC article. Clinical Trial.
-
Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis.PLoS One. 2022 Oct 14;17(10):e0275936. doi: 10.1371/journal.pone.0275936. eCollection 2022. PLoS One. 2022. PMID: 36240245 Free PMC article.
-
The role of MicroRNAs as early biomarkers of asbestos-related lung cancer: A systematic review and meta-analysis.Pulmonology. 2025 Dec 31;31(1):2416792. doi: 10.1016/j.pulmoe.2024.02.002. Epub 2024 Oct 24. Pulmonology. 2025. PMID: 38402124
-
The Molecular Basis of Malignant Pleural Mesothelioma.Thorac Surg Clin. 2020 Nov;30(4):383-393. doi: 10.1016/j.thorsurg.2020.08.005. Epub 2020 Sep 12. Thorac Surg Clin. 2020. PMID: 33012428 Free PMC article. Review.
Cited by
-
Regulatory mechanisms of circular RNAs during human mesenchymal stem cell osteogenic differentiation.Theranostics. 2024 Jan 1;14(1):143-158. doi: 10.7150/thno.89066. eCollection 2024. Theranostics. 2024. PMID: 38164139 Free PMC article. Review.
-
Network Pharmacology Approaches Used to Identify Therapeutic Molecules for Chronic Venous Disease Based on Potential miRNA Biomarkers.J Xenobiot. 2024 Oct 15;14(4):1519-1540. doi: 10.3390/jox14040083. J Xenobiot. 2024. PMID: 39449424 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical